DIET ADHERENCE INTERVENTION FOR DYSLIPIDEMIA (DIETAID)

描述：(改编自调查人员摘要)血脂异常是一种严重的 冠心病的危险因素。在血脂异常患者中， 饮食干预可以对总胆固醇和 低密度脂蛋白-胆固醇水平，从而降低患者的冠心病风险。虽然 饮食咨询可以有效地改变饮食行为，它被用于 由医生和他们的病人可变的。《饮食援助》(节食依从性 干预血脂异常)是一种基于电话的自动化系统， 起到内科医生或营养师-延伸器的作用。使用NCEP步骤I 以指南为依据，Dietaid监测血脂异常的饮食行为 并为他们提供营养信息和 建议和行为反馈影响他们的饮食行为。Dietaid 使用计算机控制的语音来说话。患者通过以下方式进行交流 按下他们按键电话上的按键。对话发生在 每周1-2次；Dietaid或患者都可以发起呼叫。 Dietaid基于电话连接通信(TLC)技术 以前由调查人员开发并成功应用于 提高患者的服药依从性和体力活动水平。一个 Dietaid的最初版本是在随机试验中开发和测试的 受控的试点研究，并被证明在降低总 血脂异常患者的胆固醇和可能的低密度脂蛋白-胆固醇。Dietaid 用户对该节目也非常满意(平均评分为8分，1分 (低)到10(高)等级)。 在这个拟议的项目中，Dietaid的试点版本将被改进为 最终版本，然后就其对饮食的影响进行评估 一项随机临床研究中的行为、营养摄入量和血脂水平 360例全科患者总胆固醇240~299 mg/dL的临床研究 一进门。受试者将被随机分配到Dietaid或TLC对照组 提供一般健康信息的干预措施。少数人 参与率预计为19%-22%，约60%的受试者 将是女性。每个科目都将接受为期六个月的跟踪调查 在基线、3个月和6个月时进行评估。这些端点将是 饮食行为的变化(高动脉粥样硬化食物的使用水平)， 定量营养素摄入量(脂肪和胆固醇)和血脂水平。 患者用户对Dietaid的接受度将通过 态度问卷，包括结构化问卷和开放式问卷 问题。Dietaid的运营成本和成本效益将是 计算出来的。

DESCRIPTION: (Adapted from Investigator's Abstract) Dyslipidemia is a major risk factor for coronary heart disease (CHD). In dyslipidemia patients, dietary interventions can have a positive impact on total cholesterol and LDL-cholesterol levels and thus reduce the patients' CHD risk. Although dietary counseling can be effective in changing dietary behavior, it is used variably by physicians and their patients. DietAid (Diet Adherence Intervention for Dyslipidemia) is an automated telephone-based system that functions as a physician or nutritionist-extender. Using the NCEP Step I guidelines as the basis, DietAid monitors dietary behavior of dyslipidemia patients in their homes and provides them with nutritional information and advice and behavioral feedback to affect their dietary behavior. DietAid uses computer-controlled speech to speak. The patients communicate by depressing keys on their touch-tone telephones. Conversations take place 1-2 times a week; either DietAid or the patient can initiate a call. DietAid is based on the Telephone-Linked Communication (TLC) technology previously developed by the investigators and successfully applied to improving medication adherence and physical activity levels in patients. An initial version of DietAid was developed and tested in a randomized controlled pilot study, and was shown to be effective in lowering total cholesterol and possibly LDL-cholesterol in dyslipidemia patients. DietAid users were also very satisfied with the program (mean rating of 8 on a 1 (low) to 10 (high) scale). In this proposed project, the pilot version of DietAid will be refined into a final version and then evaluated with regard to its effect on dietary behavior, nutrient intake and serum lipid levels in a randomized clinical trial of 360 general medical patients with total cholesterol 240-299 mg/dL on entry. Subjects will be randomly assigned to DietAid or a TLC control intervention that provides general health information. The minority participation rate is expected to be 19-22%, and about 60% of the subjects will be female. Each subject will be followed for a six month period with assessments at baseline, 3 months and 6 months. The endpoints will be changes in dietary behavior (level of use of highly atherogenic foods), quantitative nutrient intake (fat and cholesterol), and serum lipid levels. The acceptability of DietAid to patient users will be measured by an attitudinal questionnaire that includes both structured and open-ended questions. DietAid's operating costs and cost effectiveness will be calculated.